Neurocrine Biosciences (NBIX) Prepares for Key Investor Conferences in September 2025

Neurocrine Biosciences Engages Investors with Upcoming Conference Presentations

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) actively prepares for an array of investor conferences scheduled for September 2025. The company’s participation aims to enhance its visibility within the biopharmaceutical landscape, focusing on neuroscience and neurological disorders. Chief Financial Officer Matt Abernethy, Chief Commercial Officer Eric Benevich, and Vice-President of Investor Relations Todd Tushla represent Neurocrine at the Cantor Global Healthcare Conference on September 3 at 1:00 p.m. ET. This event serves as a platform to communicate the company’s strategic objectives and ongoing developments in its diverse treatment pipeline.

Following the Cantor conference, key executives, including Chief Executive Officer Kyle Gano and Chief Medical Officer Sanjay Keswani, present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 at 10:45 a.m. ET. Neurocrine’s leadership is expected to discuss the impact of their FDA-approved therapies and the advancements in their research initiatives. The subsequent Baird 2025 Global Healthcare Conference on September 10 will see Gano, Keswani, and Tushla share insights into the company's strategies for addressing complex neurological and neuropsychiatric disorders, emphasizing its commitment to innovation and patient care.

On September 17, Neurocrine executives will present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry and Epilepsy Virtual Summit. This presentation highlights Neurocrine's dedication to exploring novel therapeutic mechanisms in challenging areas such as epilepsy and neuropsychiatric disorders. The company’s robust pipeline of treatments reflects over three decades of experience, focusing on alleviating patient suffering through targeted and innovative scientific approaches. Live webcasts of these presentations will be available on Neurocrine’s website, allowing wider access to stakeholders interested in the company’s developments.

Neurocrine Biosciences continues to position itself as a leader in the biopharmaceutical industry by addressing significant unmet medical needs. With a strong commitment to research and development, the company is determined to provide effective solutions for patients suffering from neurological disorders. As these conferences unfold, the insights shared by Neurocrine’s leadership will undoubtedly shape the discourse around treatment options in the neuroscience sector.

For more details on Neurocrine Biosciences and its upcoming presentations, stakeholders can visit the company’s website or follow its updates on social media platforms.